Top Markets
#1 Ontology Gas Ontology Gas +26.62%
#2 EXOD EXOD +22.08%
#3 Status Status +17.01%
#4 Derive Derive +8.72%
#5 Gas Gas +7.44%
#6 Fake World Assets Fake World Assets +6.08%
#7 aelf aelf +5.83%
#8 Tornado Cash Tornado Cash +5.44%
#9 B3 (Base) B3 (Base) +5.37%
#10 DeFi Kingdoms DeFi Kingdoms +5.13%
Coin of the day
Ontology Gas Ontology Gas
Settings
Language
ENGLISH
Currency
USD
Theme
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc.

VICP
Rank in Stocks #25718
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
Share Price
$1.45
Last synced: 2026-08-19
Market Cap
$46.94M
Change (1 day)
0.00%
Change (1 year)
-18.08%
Country
US
Trade Vicapsys Life Sciences, Inc. (VICP)

Category

Healthcare
P/S ratio for Vicapsys Life Sciences, Inc. (VICP)
P/S ratio as of 2026 TTM: 0
According to Vicapsys Life Sciences, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Vicapsys Life Sciences, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US